Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Kansas Business Today.
Press releases published on May 12, 2025
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 million Transaction …
BLINK CHARGING ANNOUNCES FIRST QUARTER 2025 RESULTS
GlobeNewswire
·
May 12, 2025
First quarter 2025 total revenues of $20.8 million First quarter 2025 service revenues grew 29.2% to $10.6 million compared to $8.2 million in first quarter of 2024 Gross margin of 35.5% in the first quarter of 2025 During the first quarter the Company …
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
GlobeNewswire
·
May 12, 2025
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial …
MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended March 31, 2025
GlobeNewswire
·
May 12, 2025
Results for the Quarter Ended March 31, 2025 and Other Recent Highlights: Net investment income per share for the quarter was $0.37 Net asset value per share as of the end of the quarter was $14.93, compared to $14.98 as of December 31, 2024, a decrease of …
EloMaas Under Review: The Wild Stallion Pro Herbal Science Breakthrough Formula to Support Sexual Health (StalliOnX)
GlobeNewswire
·
May 12, 2025
New York, May 12, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: The real reasons behind common male sexual health challenges, including low stamina, reduced drive, and hormonal imbalance How EloMaas featuring Wild Stallion Pro positions itself …
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first …
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval Company to host …
Stereotaxis Reports 2025 First Quarter Financial Results
GlobeNewswire
·
May 12, 2025
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. “We’ve …
HighPeak Energy, Inc. Announces First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 12, 2025
FORT WORTH, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended March 31, 2025, provided an updated 2025 development outlook and …
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
GlobeNewswire
·
May 12, 2025
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, …
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from …
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire
·
May 12, 2025
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) …
Assertio Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) …
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 …
CompoSecure Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
Operating results in line with expectations Reiterating previously issued full-year 2025 guidance Completed spin-off of Resolute Holdings Management, Inc. (Nasdaq: RHLD) Accounting standards related to the spin-off require the Company to report results …
Resolute Holdings Reports First Quarter 2025 Results
GlobeNewswire
·
May 12, 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (Nasdaq: RHLD), an operating management company responsible for providing management services to CompoSecure Holdings, L.L.C. (“CompoSecure Holdings”), a …
Priority Income Fund Announces Redemption of its 6.625% Series F Term Preferred Stock Due 2027
GlobeNewswire
·
May 12, 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Priority Income Fund, Inc. (“Priority Income Fund” or the “Fund”) announced today that it will redeem all outstanding shares of its 6.625% Series F Term Preferred Stock Due 2027 (CUSIP: 74274W 822; NYSE: PRIF PRF) …
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
GlobeNewswire
·
May 12, 2025
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R…
Plug Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
SLINGERLANDS, N.Y., May 12, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions, today announced its financial results and operational milestones for the first quarter ended March 31, 2025. The …
CPS Announces First Quarter 2025 Earnings
GlobeNewswire
·
May 12, 2025
Revenues of $106.9 million compared to $91.7 million in the prior year period Net income of $4.7 million, or $0.19 per diluted share Total portfolio balance of $3.615 billion, highest in company history New contract purchases of $451.2 million LAS VEGAS, …